A sub-study showed that even in patients already receiving high doses of RAAS-blocking drugs, additional neprilysin inhibition slows the decline in estimated GFR (follow-up of up to 44 months), especially in patients with diabetes (0.6 mL/min per 1.73 m2 yr vs. 0.3 mL/min per 1.73 m2 yr; p = 0.038). Here, MME is linked to diabetes mellitus.